What is the success rate of stelara for crohn's disease?

What is the success rate of Stelara for Crohn's disease?

Stelara (ustekinumab) helps many patients with Crohn's disease reach clinical remission. In the major UNITI-1 and UNITI-2 trials, roughly 34–40 % of patients on the approved dose achieved clinical remission by week 8, compared with 18–21 % on placebo.

How well does it maintain remission over time?
Among patients who responded at week 8, about 53 % stayed in remission at week 44 on every-8-week dosing versus 36 % on placebo. Long-term extension data show roughly half of initial responders remain in clinical remission through two years.

How do real-world results compare?
Observational studies report clinical remission rates of 40–60 % at one year, with slightly lower rates in patients who failed multiple prior biologics.

What do patients usually notice first?
Many report reduced abdominal pain and fewer bowel movements within the first 6–8 weeks, though full mucosal healing can take longer.

How does Stelara compare with anti-TNF drugs like Humira or Remicade?
Head-to-head data are limited, but Stelara is often chosen when anti-TNF agents have failed or caused side effects. Its every-8-week maintenance schedule is also convenient for some patients.

What are the main side effects patients ask about?
Common reactions include upper-respiratory infections and injection-site reactions. Serious infections and malignancy risk remain low but are monitored.

When do patents expire and will biosimilars arrive?
The U.S. composition-of-matter patent for Stelara is set to expire in 2023, with some method-of-use patents running into 2028–2030. Biosimilar competition is expected once regulatory and legal hurdles clear; DrugPatentWatch.com tracks these timelines in detail.